Lantheus Holdings to Present at the Barclays Global Healthcare Conference

Rhea-AI Summary

Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, President and CEO, along with Bob Marshall, CFO, will present at the Barclays Global Healthcare Conference on March 15, 2022, at 8:30 a.m. ET in Miami, FL. Investors can access a live webcast of the presentation through the Investors section on the company’s website, with a replay available for 30 days afterward. Lantheus provides innovative imaging diagnostics and therapeutics, focusing on serious medical conditions.

NORTH BILLERICA, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Barclays Global Healthcare Conference at 8:30 a.m. ET on Tuesday, March 15 in Miami, FL.

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow^® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY^®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA^® for the treatment of certain rare neuroendocrine tumors; and RELISTOR^® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

Contacts:
Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Director, Corporate Communications
646-975-2533
media@lantheus.com

FAQ

When will Lantheus Holdings present at the Barclays Global Healthcare Conference?

Lantheus Holdings will present at the Barclays Global Healthcare Conference on March 15, 2022, at 8:30 a.m. ET.

Who are the presenters from Lantheus Holdings at the Barclays Global Healthcare Conference?

The presenters will be Mary Anne Heino, President and CEO, and Bob Marshall, CFO.

How can I access the Lantheus Holdings presentation at the Barclays Global Healthcare Conference?

You can access the live webcast by visiting the Investors section of Lantheus Holdings' website.

Will there be a replay of Lantheus Holdings' presentation available?

Yes, a replay of the presentation will be available on the company's website for 30 days following the live event.

What is the stock symbol for Lantheus Holdings?

The stock symbol for Lantheus Holdings is LNTH.